Home › Funds › Viking Global Investors › BMRN

Viking Global Investors position in BMRN

BIOMARIN PHARMACEUTICAL INC · Health Care

Viking Global Investors reported holding 7,173,173 shares of BMRN (BIOMARIN PHARMACEUTICAL INC) in its Q3 2026 13F filing — a position valued at US$430.4M, representing 1.32% of its reported portfolio and ranking #34 among its reported holdings. Viking Global Investors has disclosed BMRN holdings in 20 of the last 20 reported quarters, going back to Q4 2021.

Latest position (Q3 2026)7.17M sh
Reported value held$430.39M
Portfolio Weight1.32%
First reportedQ4 2021
Last changeReduce
Updated2026-11-17

Last updated: 2026-11-17 · Source: SEC EDGAR Form 13F-HR

How Viking Global Investors's BMRN position evolved

Viking Global Investors first disclosed a stake in BMRN in Q4 2021 at 2,869,947 shares (US$253.6M). The position peaked in Q1 2025 at 10,800,059 shares, worth US$763.5M. Across 20 filings, Viking Global Investors increased the stake 15 time(s), trimmed it 4 time(s) and left it unchanged 0 time(s). The most recent filing (Q3 2026) shows 7,173,173 shares valued at US$430.4M — a reduction of -443,390 shares quarter over quarter.. Notable position changes include a 59% trim in Q1 2023 (shares fell 11% over the following quarter), a 92% increase in Q2 2023 (shares rose 2% over the following quarter), a 38% increase in Q3 2024 (shares fell 6% over the following quarter).

Quarter by quarter

QuarterSharesValueChange
Q4 2021 2.87M $253.56M New
Q1 2022 3.75M $289.31M Add
Q2 2022 5.05M $418.71M Add
Q3 2022 5.10M $432.26M Add
Q4 2022 5.27M $545.77M Add
Q1 2023 2.17M $210.88M Reduce
Q2 2023 4.16M $360.31M Add
Q3 2023 4.22M $372.98M Add
Q4 2023 4.89M $471.44M Add
Q1 2024 6.42M $560.40M Add
Q2 2024 7.06M $581.54M Add
Q3 2024 9.75M $685.56M Add
Q4 2024 10.51M $690.86M Add
Q1 2025 10.80M $763.46M Add
Q2 2025 12.29M $675.50M Add
Q3 2025 8.32M $450.73M Reduce
Q4 2025 6.04M $358.78M Reduce
Q1 2026 7.06M $398.94M Add
Q2 2026 7.62M $435.82M Add
Q3 2026 7.17M $430.39M Reduce

Dots on the line are colored by change type; missing quarters mean no position was reported.

About BMRN and 13F data

BMRN (BIOMARIN PHARMACEUTICAL INC) is a Health Care company. 24 other funds we track also report a position in BMRN — the largest reported positions include PRIMECAP MANAGEMENT CO/CA/ (US$899.3M), VIKING GLOBAL INVESTORS LP (US$430.4M), Deep Track Capital, LP (US$382.5M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.

Other funds holding BMRN

All BMRN fund holders →

FAQ

How long has Viking Global Investors held BMRN?

Viking Global Investors has disclosed BMRN holdings in 20 of the last 20 reported quarters, going back to Q4 2021.

What is Viking Global Investors's current position in BMRN?

As of Q3 2026, Viking Global Investors holds 7.17M shares of BMRN (BIOMARIN PHARMACEUTICAL INC), valued at $430.39M, representing 1.32% of its reported portfolio and ranking #34.

Has Viking Global Investors been buying or selling BMRN?

In the latest 13F filing (Q3 2026), Viking Global Investors reduced its position in BMRN. The position peaked in Q1 2025 at 10.80M shares.

Which other funds hold BMRN?

Other major institutional holders of BMRN include PRIMECAP MANAGEMENT CO/CA/, VIKING GLOBAL INVESTORS LP, Deep Track Capital, LP, among 24 funds with disclosed positions.

Where does this data come from?

All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.